20.33
20.33 (0%)
As of Feb 14, 2025
Immunovant, Inc. [IMVT]
Source:
Company Overview
Immunovant, Inc is a clinical-stage immunology company pursuing a broad anti-FcRn strategy based on the potential best-in-class profile of our lead asset, IMVT-1402, and informed by the breadth of the class, in which 23 indications have been publicly announced for study by multiple companies to date.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | ( 917 ) 580-3099 |
| Industry | manufacturing |
| CEO | Peter Salzmann |
| Website | www.immunovant.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | |
| Net Income | $-51.4 |
| Net Cash | $314.4 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -9.2% |
| Profit as % of Stockholder Equity | -7.6% |
Management Effectiveness
| Return on Equity | -7.6% |
| Return on Assets | -7.2% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $711.4 |
| Total Liabilities | $32.1 |
| Operating Cash Flow | $-154.5 |
| Investing Cash Flow | $-0.2 |
| Financing Cash Flow | $470.9 |
